Potential Failure of Vancomycin Dosing Using AUC/MIC in a Patient With Purulent Methicillin-Resistant Staphylococcus...

Area of Science:

• Infectious Diseases
• Pharmacology
• Cardiology

Background:

• Purulent pericarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a rare and serious condition.
• Current guidelines recommend vancomycin therapy guided by area under the curve (AUC)/minimum inhibitory concentration (MIC) for MRSA bacteremia.
• Treatment strategies for MRSA purulent pericarditis remain limited, with evidence primarily from case reports.

Observation:

• A 57-year-old male presented with cardiac tamponade and pulmonary emboli secondary to MRSA purulent pericarditis.
• Initial vancomycin therapy (AUC 415) was complicated by fluctuating MIC values in repeat blood cultures, indicating persistent bacteremia.
• Despite vancomycin, the patient experienced prolonged bacteremia for 8 days.

Findings:

• The patient was transitioned to daptomycin and ceftaroline, achieving blood culture clearance within 48 hours.
• Inconsistent MIC results highlight potential variability in vancomycin efficacy and diagnostic methods.
• This case underscores the complexities of AUC/MIC vancomycin dosing when MIC values fluctuate.

Implications:

• Further research is needed to standardize MIC determination methods for vancomycin in MRSA infections.
• Optimal vancomycin dosing strategies (AUC/MIC) for MRSA purulent pericarditis require further investigation.
• Effective management of MRSA purulent pericarditis is critical due to high associated mortality.